ENCAVIS AG

  • WKN: 609500
  • ISIN: DE0006095003
  • Land: Deutschland

Nachricht vom 18.10.2021 | 17:40

ENCAVIS AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

ENCAVIS AG
18.10.2021 / 17:40
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

PELABA Vermögensverwaltungs GmbH & Co. KG, Prof.-Messerschmitt-Str. 1 D-85579 Neubiberg , Germany informed us on October 06, 2021 pursuant to Art. 43(1) WpHG thereby making reference to the exceedance of the threshold of 10% or a higher threshold from September 28, 2021 , as follows:

  • The investment is used to implement strategic objectives.
  • The reporting person does not intend to obtain further voting rights by acquisition or any other way.
  • The reporting person does not intend to influence the composition of the issuers' administration, management or supervisory board.
  • The reporting person does not intend to change the capital structure of the company, especially with regards to the ratio of internal/outside financing and the dividend policy.
  • Concerning the source of funds, the capital is financed by 100% through equity capital with which the reporting person needs to finance the acquisition of the voting rights.



18.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021